The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
|
|
- Valerie Parks
- 5 years ago
- Views:
Transcription
1 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. A Proposal for a New Staging System. Toyonori Tsuzuki, Toshinori Nishikimi, Yota Murase, Hidehiro Iwata Aichi Medical University Hospital
2 The 30 th European Congress of Pathology Conflict of Interest (COI) Presenter: Toyonori Tsuzuki The author has no conflict of interest to disclose with respect to this presentation. Department of Surgical Pathology Aichi Medical University Hospital
3 Background The AJCC/UICC TNM classification is the gold standard to predict bladder cancer outcome. The paradigm of pathological stage (pt) categorization in bladder cancer remains the depth of tumor invasion into the different histologic layers of the bladder wall. However, the structure of these layers differs from their anatomic site.
4
5 AJCC/UICC pt staging 8 th edition TX T0 Ta Tis T1 T2 Primary tumor Primary tumor cannot be assessed No evidence of primary tumor Noninvasive papillary carcinoma Carcinoma in situ Tumor invades subepithelial connective tissue (lamina propria) Tumor invades musclularis propria T2a Tumor invades superficial muscularis propria (inner half) T2b Tumor invades deep muscularis propria (outer half) T3 T4 Tumor invades perivesical tissue T3a Microscopically T3b Macroscopically (extravesical mass) Tumor invades any of the following: prostatic stroma, uterus, vagina, pelvic wall, and abdominal wall T4a T4b Tumor invades prostatic stroma* or uterus or vagina Tumor invades pelvic wall or abdominal wall
6 Background The boundary of muscularis propria and perivesical tissue is commonly ill defined. The distinction on microscopic and macroscopic (pt3a vs pt3b) perivesical tissue is usually subjective. Therefore, the current TNM staging system demonstrates wide prognostic variability within each primary tumor stage.
7
8 Am J Surg Pathol. 2014;38 :167-75
9 Am J Surg Pathol. 2014;38 :167-75
10 Background The boundary of muscularis propria and perivesical tissue is commonly ill defined. The distinction on microscopic and macroscopic (pt3a vs pt3b) perivesical tissue is usually subjective. Therefore, the current TNM staging system demonstrates wide prognostic variability within each primary tumor stage.
11 Aim To develop a new pt staging system improving the objectivity and accuracy of prognosis in bladder cancer by integrating the depth of tumor invasion.
12 Methods We enrolled 117 muscle invasive urothelial carcinoma of the bladder patients between May 2004 to December No patients had distant metastasis. No patients received adjuvant and/or neoadjuvant chemotherapy. We reviewed the all slides and selected the slides showing deepest tumor invasion from the normal urothelium.
13 Methods pt2 (AJCC/UICC) (Tumor invades into the musclaris propria.) pt3(ajcc/uicc) (Tumor invades into the perivesicular tissue.) Normal urothelium The depth of tumor invasion was measured from the normal urothelium to the deepest tumor invasion.
14
15 Results Clinical characteristics No. patients 117 Male : female ratio 78:39 Patient s age (median) (71) Follow-up duration (median) months (32) No. developed recurrence 72 No. died of the disease 55 No. died of other causes 14
16 Analyzed prognostic valuables Depth of tumor invasion (mm) Pathological T stage (pt) 1973WHO grade (G1, G2, G3) Lymphovascular invasion Lymph node metastasis Concomitant CIS Age
17 Pathological characteristics Depth of tumor invasion(median) mm (10.80) pt2:pt3 38: WHO grade G2 28 G3 89 Lympho-vascular invasion Present 59 Absent 58 Lymph node metastasis Present 14 Absent 103 Concomitant CIS Present 33 Absent 84
18 Cutoff value of depth of tumor invasion Harrell C-index in COX model Harrell C-index in Fine and Gray model
19 Univariate Multivariate Pathological factor Categori N Hazard Ratio 95% CI Pvalue* Hazard Univariate Ratio 95% CI Pvalue* Depth of tumor invasion < <= (1.27, 3.51) (1.11, 3.21) Lympho-vascular invasion V V1/V (1.06, 2.84) (0.84, 2.39) Lymph node metastasis yes 14 1 no (0.29, 1.12) (0.35, 1.47) pt pt pt (0.85, 2.49) (0.60, 1.95) Age < <= (0.87, 3.08) (0.83, 3.01) WHO grade G G (0.68, 2.21) (0.58, 1.94) CIS yes 33 1 no (0.60, 1.78) (0.61, 1.90) Multivariate tor Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* n < <= (1.27, 3.51) (1.11, 3.21) sion V V1/V (1.06, 2.84) (0.84, 2.39) is yes 14 1 no (0.29, 1.12) (0.35, 1.47)
20 Pathological factor Categori N Pr > ChiSq Hazard Ratio 95% CI Categori N Pr > ChiSq Hazard Ratio Depth of tumor invasion < <= Lympho-vascular invasion V V1/V Lymph node metastasis yes 14 1 no < pt pt pt Age < <= WHO V0 grade 59G G CIS yes 33 1 no % CI 10<= V1/V
21 Univariate Multivariate Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* Univariate Multivariate Pathological factor Categori N Hazard Ratio 95% CI Pvalue* Hazard Ratio 95% CI Pvalue* Depth of tumor invasion < <= (1.23, 3.52) (1.12, 3.36) Lmpho-vascular invasion V <10 55 V1/V Lymph node metastasis yes 14 1 (1.01, 2.81) (0.80, 2.40) no (0.25, 0.97) (0.28, 1.22) pt pt pt (0.76, 2.26) (0.55, 1.82) Age V0 59 < <= (0.91, 3.41) (0.93, 3.58) WHO grade G G (0.59, 1.97) (0.50, 1.73) CIS yes 14 yes no (0.71, 2.30) (0.70, 2.38) <= (1.23, 3.52) (1.12, 3.36) V1/V (1.01, 2.81) (0.80, 2.40)
22 Conclusions The depth of tumor invasion (<10 mm vs. >10 mm) was an independent prognostic factor in DFS, CSS, and OS. The depth of tumor invasion can be a novel staging system for bladder cancer, that is more objective and accurate than the current AJCC/UICC staging system in muscle invasive bladder cancer.
23 Thank you
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationPathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)
Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationTOPICS FOR DISCUSSION
INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Head and Neck Tumours Pages 20, p27, p34, p38, p41, and p49 ly pn2a Metastasis in a single ipsilateral lymph node, less than 3cm in greatest dimension with
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationUICC TNM 8 th Edition Errata
UICC TNM 8 th Edition Errata ions are in italics Page 28 Oropharynx p16 positive Pathological Stage II,T2 N2 M0 T3 N0,N1 M0 Stage II,T2 N2 M0 T3,T4 N0,N1 M0 Page 61 Oesophagus Adenocarcinoma Pathological
More informationA215- Urinary bladder cancer tissues
A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: No. of cases: 45 Tissue type: Urinary bladder cancer tissues No. of spots: 2 spots from each cancer case (90
More informationMale genital tract tumors. SiCA. Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital.
Male genital tract tumors Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital. adenocarcinoma Prostate Cancer most common male cancer in western countries more detected in
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More information6/5/2010. Renal vein invasion & Capsule Penetration (T3a) Adrenal Gland involvement (T4 vs. M1) Beyond Gerota s Fascia? (?T4).
GU Cancer Staging: Updates and Challenging Areas 13 th Current Issues in Surgical Pathology San Francisco, CA June 5, 2010 Jeffry P. Simko, PhD, MD Associate Professor Departments of Urology and Anatomic
More informationUrinary Bladder, Ureter, and Renal Pelvis
Urinary Bladder, Ureter, and Renal Pelvis Protocol applies to all carcinomas of the urinary bladder, ureter, and renal pelvis. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition Procedures
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationUterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationUpper urinary tract urothelial carcinomas (UTUC)
Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract Manel Mellouli 1 *, Slim Charfi 1, Walid Smaoui 2, Rim Kallel 1, Abdelmajid Khabir 1, Mehdi Bouacida
More informationBladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)
Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of
More informationManagement of Vulvar Cancer: How to Handle Close Margins?
Management of Vulvar Cancer: How to Handle Close Margins? Sven Mahner, MD Department of Gynecology and Obstetrics University of Munich AGO Study Group Munich, Germany Surgical Resection of Vulvar Cancer
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More informationKEYWORDS Bladder cancer, Transitional cell carcinoma, Magnetic resonance imaging, staging, Tumor node metastasis
DIAGNOSTIC ACCURACY OF MRI IN DIFFERENTIATING NON-MUSCLE INVASIVE FROM MUSCLE INVASIVE BLADDER CARCINOMA TAKING HISTOPATHOLOGICAL STAGING AS A STANDARD. Syed Muhammad Faiq 1,Khujasta Mehtab 1,Nazish Naz
More informationStaging and reporting of urothelial carcinoma of the urinary bladder
& 2009 USCAP, Inc All rights reserved 0893-3952/09 $32.00 www.modernpathology.org Staging and reporting of urothelial carcinoma of the urinary bladder Liang Cheng 1,2, Rodolfo Montironi 3, Darrell D Davidson
More informationDefinition of Synoptic Reporting
Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are
More informationPart II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by
Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationQ&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda
Collecting Cancer Data: Bladder March 3, 2011 NAACCR 2010-2011 Webinar Series Agenda Coding Moment Bladder Overview Multiple Primary Histology Rules Collaborative Stage Data Collection System Diagnostic,
More informationPrognostic factors of genitourinary tumors: Do we have to care?
Prognostic factors of genitourinary tumors: Do we have to care? Jae Y. Ro, MD, PhD Professor and Director of Surgical Pathology The Methodist Hospital, Weill Medical College of Cornell University, Houston,
More informationUnderstanding Your Pathology Report
Understanding Your Pathology Report Because every person s breast cancer is unique, it s important to understand the underlying biology of your tumor to personalize your treatment plan. Your physicians
More informationUpdate on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More informationEAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
EAU MUSLE-INVASIVE AND METASTATI LADDER ANER (Limited text update March 2016) J.A. Witjes (hair), E. ompérat, N.. owan, M. De Santis, G. Gakis, N. James, T. Lebret, A.G. van der Heijden, M.J. Ribal Guidelines
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationPatient identifiers Date of request Accession/Laboratory number. TUMOUR FOCALITY (Note 4) (Note 3)
Carcinoma of the Bladder Histopathology Reporting Guide Cystectomy, Cystoprostatectomy and Diverticulectomy Specimen Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationKey words: gastric cancer, lymphovascular invasion, recurrence
Key words: gastric cancer, lymphovascular invasion, recurrence 139 (2177) Table I Relationship between clinicopathologic factors and lymphatic invasion in 2146 patients with gastric cancer Factors P-value
More informationEtiology and diagnosis of bladder cancer
Etiology and diagnosis of bladder cancer Introduction Incidence: the most common urothelial tumor, representing the 2 nd most common urological tumor in men (4 th in overall frequency) and the 1 st in
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationQuestion: If in a particular case, there is doubt about the correct T, N or M category, what do you do?
Exercise 1 Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do? : 1. I mention both categories that are in consideration, e.g. pt1-2 2. I classify as
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationCorrelation of intermediate risk factors with prognostic factors in patients with early cervical cancer
대한부인종양콜포스코피학회제 24 차학술대회 Correlation of intermediate risk factors with prognostic factors in patients with early cervical cancer Seoul National University Bundang Hospital Eun Jung Soh, M.D. Cervical cancer
More informationStaging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates
Staging Challenges in Lower GI Cancers Sanjay Kakar, MD University of California, San Francisco March 05, 2017 Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education
More informationGastric Cancer Staging AJCC eighth edition. Duncan McLeod Westmead Hospital, NSW
Gastric Cancer Staging AJCC eighth edition Duncan McLeod Westmead Hospital, NSW Summary of changes New clinical stage prognostic groups, ctnm Postneoadjuvant therapy pathologic stage groupings, yptnm -
More information25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES
25 TH ICRO DEHRADUN STAGING OF GENITOURINARY MALIGNANCIES SPEAKER DR DEEPAK ABROL CLINICAL ONCOLOGIST JAND K HEALTH SERVICES CONSULTANT ONCOLOGIST MAHARISHI DAYANAND HOSPITAL AND MEDICAL RESEARCH CENTER
More informationUrological Oncology. Dae Hyeon Kwon, Phil Hyun Song, Hyun Tae Kim.
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.7.457 Urological Oncology Multivariate Analysis of the Prognostic Significance of Resection Weight after Transurethral Resection of Bladder Tumor
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationGastric Cancer Histopathology Reporting Proforma
Gastric Cancer Histopathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.01). S1.01 Identification Family name Given name(s) Date of birth Sex Male Female Intersex/indeterminate
More informationCan MRI Improve Triage of Bladder Cancer Patients. John Chang, M.D., Ph.D. Banner MD Anderson Cancer Center
Can MRI Improve Triage of Bladder Cancer Patients John Chang, M.D., Ph.D. Banner MD Anderson Cancer Center None Financial Disclosures MRI for Bladder Cancer Background Bladder cancer staging and treatment
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationNeoplasms of the Prostate and Bladder
Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationNUMERATOR: Reports that include the pt category, the pn category and the histologic grade
Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationIs Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer?
Is Hepatic Resection Needed in the Patients with Peritoneal Side T2 Gallbladder Cancer? Lee H, Park JY, Youn S, Kwon W, Heo JS, Choi SH, Choi DW Department of Surgery, Samsung Medical Center Sungkyunkwan
More informationColon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition
Colon and Rectum Protocol applies to all invasive carcinomas of the colon and rectum. Carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix are excluded. Protocol revision date: January
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationL ARYNX S TAGING F ORM
CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left
More information5/26/16: CT scan of the abdomen showed a multinodular liver disease highly suspicious for metastasis and hydronephrosis of the right kidney.
Bladder Case Scenario 1 History 5/23/16: A 52-year-old male, smoker was admitted to our hospital with a 3-month history of right pelvic pain, multiple episodes of gross hematuria, dysuria, and extreme
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationEssentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis
73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled
More informationLarge blocks in prostate and bladder pathology
Large blocks in prostate and bladder pathology Farkas Sükösd Department of Pathology, University of Szeged The history of the large block technique in radical prostatectomy and cystectomy The first large
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationBladder Cancer Early Detection, Diagnosis, and Staging
Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationEuropean Association of Urology. Pocket Guidelines edition
European Association of Urology Pocket Guidelines 2012 edition Introduction The EAU Guidelines Office is pleased to present the 2012 edition of the Pocket Guidelines. These ultra-short versions of Europe
More informationUICC 8 th Edition Errata 25 th of May 2018
UICC 8 th Edition Errata 25 th of May 2018 ions are in italics Head and Neck Tumours Page 19 Oral Cavity T2 T3 T4a Tumour 2 cm or less in greatest dimension and more than 5 mm but no more than 10 mm depth
More informationThis form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More information